Progestagens in high-risk pregnancy. What we know today

Author:

Pedachenko N.Y.1ORCID,Goncharuk N.P.2ORCID,Chaikivska E.F.3ORCID,Tatarchuk T.F.4ORCID,Tutchenko T.M.5ORCID

Affiliation:

1. P.L. Shupyk National University of Health Care of Ukraine, Kyiv, Ukraine

2. P.L. Shupyk National Healthcare University of Ukraine, Kyiv City Maternity Hospital No. 1, Kyiv, Ukraine

3. Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

4. SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine”, Kyiv, Ukraine

5. SI “O.M. Lukyanova Institute of Pediatrics, Obstetrics and Gynecology of the NAMS of Ukraine”; SSI “Center for Innovative Medical Technologies of the NAS of Ukraine»; “DILA” Medical Laboratory, Kyiv, Ukraine

Abstract

Miscarriage remains an important global problem: 23 million miscarriages are registered annually in the world, i.e. 44 pregnancy losses every minute, and the total risk of miscarriage is 15.3% of all pregnancies. Effective methods of pregnancy preservation (in case of idiopathic miscarriage and threatened miscarriage) include lifestyle modification and progestagen therapy. Progesterone is the main hormone necessary to maintain pregnancy.The effectiveness of progestogens among medical methods that increase the chances of pregnancy preservation has been proven by numerous studies. Effectiveness and safety of various types of progestogens during pregnancy have been studied. As a result, progesterone and dydrogesterone became the only progestogens approved for use in obstetrics – micronized progesterone and dydrogesterone reduce the frequency of miscarriage in women with clinical diagnoses of threatened miscarriage and idiopathic recurrent miscarriage. In addition, the progestogens safety has been carefully studied in modern randomized studies, prospective trials and meta-analyses and the same safety profile of dydrogesterone and micronized progesterone for pregnant women and the fetus has been proven.Studies have shown that oral dydrogesterone has relatively low antagonistic activity at glucocorticoid and mineralocorticoid receptors compared to progesterone and therefore well tolerated. Oral dydrogesterone due to the peculiarities of structure has improved bioavailability compared to progesterone, which allows a woman to avoid the inconvenience and discomfort associated with the intravaginal or intramuscular use of progesterone. In addition, dydrogesterone has a 1.5 times higher affinity for progesterone receptors compared to micronized progesterone and a pronounced anti-inflammatory and immunomodulation effect, which provides certain clinical advantages for patients after recurrent pregnancy losses.Thus, progestogens are indicated for all patients with recurrent pregnancy losses from the moment of receiving a positive pregnancy test, as they reduce the risk of miscarriage. It is important that the use of progestagen drugs during the first and second trimester of pregnancy is not associated with side effects

Publisher

Publishing Office TRILIST

Subject

Obstetrics and Gynecology,Reproductive Medicine,Endocrinology, Diabetes and Metabolism

Reference53 articles.

1. World Health Organization. Definitions and indicators in family planning and maternal and child health and reproductive health (2021). Available from: [https://apps.who.int/iris/bitstream/handle/10665/108284/E68459.pdf?seq], last accessed 09.02.2023.

2. Quenby, S., Gallos, I.D., Dhillon-Smith, R.K., et al. “Miscarriage matters: the epidemiological, physical, psychological, and economic costs of early pregnancy loss.” Lancet 397.10285 (2021): 1658–67. DOI: 10.1016/S0140-6736(21)00682-6

3. Cumming, G.P., Klein, S., Bolsover, D., et al. “The emotional burden of miscarriage for women and their partners: trajectories of anxiety and depression over 13 month.” BJOG 114.9 (2007): 1138–45. DOI: 10.1111/j.1471-0528.2007.01452.x

4. Engelhard, I.M., van den Hout, M.A., Arntz, A. “Posttraumatic stress disorder after pregnancy loss.” Gen Hosp Psychiatry 23.2 (2001): 62–6. DOI: 10.1016/s0163-8343(01)00124-4

5. National Institute for Health and Care Excellence. Ectopic pregnancy and miscarriage: diagnosis and initial management. NICE guideline [NG126]. Published: 17 April 2019. Last updated: 24 November (2021). PMID: 31393678. Bookshelf ID: NBK544906.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3